Next Steps For The Patient With Persistent Genital Arousal Disorder
Learning Objectives and CME/Disclosure Information
This activity is intended for healthcare providers delivering care to women and their families.
After completing this activity, the participant should be better able to:
1. Utilize the appropriate questions to determine the diagnosis of PGAD 2. List potential treatment options for PGAD
Estimated time to complete activity: 0.25 hours
Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.
Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Method of Participation and Request for Credit
Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.
Persistent Genital Arousal Disorder is characterized by significant unwanted feelings of arousal that are not associated with sexual desire and are not resolved with multiple orgasms. It is important to determine that the patient does indeed meet the diagnosis of Persistent Genital Arousal Disorder (PGAD). The history and patient’s description is critical.
Ask and elicit the following
Is the arousal related in any way to sexual stimulus or thoughts?
Can the patient alleviate the symptoms by inducing and experiencing four or fewer orgasms?
In what way is the patient experiencing distress?
Provide support for the patient, acknowledging the severity of the condition. PGAD patients can often feel dismissed or frustrated by how debilitating this condition can be
Patients with PGAD complain of intense feelings of genital arousal which are spontaneous, unconnected to sexual desire or activity and persistent, lasting hours, days or weeks. This condition is often accompanied by severe anxiety or depression as the symptom can be disruptive and debilitating. Treatment generally involves managing symptoms to allow normal day to day activity.
PGAD is a fairly new diagnosis and while there are numerous treatments for the condition, there is currently no one absolute way of resolving the symptoms. The following are treatments that are used to minimize PGAD symptoms and allow for continuation of a relatively normal routine:
If PGAD onset began with the prescription of Selective Serotonin Reuptake Inhibitors (SSRIs), patient may consider discontinuing them, if possible, under the guidance of the prescribing physician
Similarly, if the condition began when the patient stopped taking an SSRI, they can consider restarting them under the guidance of the prescribing physician
Valium suppositories if the condition is accompanied by vaginal spasm
TENS unit used one or more times during the day on the vulva
Pudendal nerve blocks
Short term treatment of alprazolam can be helpful in alleviating symptoms while more long term solutions are found
This condition is often relapsing/remitting, that is patient have “flare ups” and then the condition can quiet down for long periods of time
Encourage patients to get psychological support
Cognitive behavioral therapy (e.g., mindfulness meditation) has been reported as a potential treatment modality
A general therapist who deals with chronic pain or sex therapist would be suitable for patients during times when the condition manifests symptoms and while they are looking for appropriate treatment
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan